Inhibikase Therapeutics, Inc. financial data

Symbol
IKT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
3350 Riverwood Parkway Se, Suite 1900, Atlanta, GA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 736 % +4.74%
Debt-to-equity 15.7 % -8.41%
Return On Equity -104 % +3.67%
Return On Assets -89.6 % +2.43%
Operating Margin -2.01B % -32475675%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74.3M shares +1048%
Common Stock, Shares, Outstanding 69.4M shares +1021%
Entity Public Float 7.7M USD -59.7%
Common Stock, Value, Issued 69.4K USD +1021%
Weighted Average Number of Shares Outstanding, Basic 23.7M shares +293%
Weighted Average Number of Shares Outstanding, Diluted 23.7M shares +293%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 17.2M USD +26.4%
Costs and Expenses 28.6M USD +40.5%
Operating Income (Loss) -28.6M USD -42.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -27.5M USD -44.6%
Earnings Per Share, Basic -1.16 USD/shares +63.3%
Earnings Per Share, Diluted -1.16 USD/shares +63.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 56.5M USD +514%
Marketable Securities, Current 41.1M USD +905%
Assets, Current 98.5M USD +593%
Property, Plant and Equipment, Net 47.1K USD -35.8%
Operating Lease, Right-of-Use Asset 101K USD -54.4%
Assets 98.6M USD +580%
Accounts Payable, Current 943K USD +45.8%
Accrued Liabilities, Current 2.68M USD +18.6%
Liabilities, Current 3.73M USD +8.58%
Operating Lease, Liability, Noncurrent 25.6K USD -82.9%
Liabilities 3.73M USD +5.81%
Accumulated Other Comprehensive Income (Loss), Net of Tax -37.2K USD -4347%
Retained Earnings (Accumulated Deficit) -94.4M USD -41.1%
Stockholders' Equity Attributable to Parent 94.9M USD +764%
Liabilities and Equity 98.6M USD +580%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.87M USD +35.2%
Net Cash Provided by (Used in) Financing Activities 367K USD -95.7%
Net Cash Provided by (Used in) Investing Activities -3.31M USD +43.3%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 69.4M shares +1021%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 56.5M USD +516%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 23.2M USD +23.8%
Deferred Tax Assets, Gross 23.2M USD +23.8%
Operating Lease, Liability 111K USD -54%
Depreciation 26.3K USD -85.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.78M USD -25.7%
Lessee, Operating Lease, Liability, to be Paid 153K USD
Property, Plant and Equipment, Gross 104K USD 0%
Operating Lease, Liability, Current 152K USD +2.88%
Lessee, Operating Lease, Liability, to be Paid, Year Two 115K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 38.3K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.45K USD -82.1%
Deferred Tax Assets, Operating Loss Carryforwards 12.3M USD +34.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 8.14M USD +1528%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%